1243262-17-0

Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models[1][2][3].

[1] Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. DOI:10.1158/1078-0432.CCR-14-1373
[2] Fischer?M, et al.?Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res?2011;71:1520-5. DOI:10.1158/0008-5472.CAN-10-2817
[3] Hoey?T, et al.?DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell?2009;5:168–77. DOI:10.1016/j.stem.2009.05.019
[4] Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608. DOI:10.7150/thno.48067